NanoRepro AG (NN6) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NanoRepro AG (NN6) has a cash flow conversion efficiency ratio of 0.055x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.05 Million ≈ $2.40 Million USD) by net assets (€37.30 Million ≈ $43.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NanoRepro AG - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how NanoRepro AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of NanoRepro AG for a breakdown of total debt and financial obligations.
NanoRepro AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NanoRepro AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Indivior PLC
LSE:INDV
|
-0.612x |
|
Smithson Investment Trust PLC
LSE:SSON
|
0.000x |
|
Tuju Setia Bhd
KLSE:5297
|
-0.334x |
|
Higher Way Electronic Co Ltd
TWO:3268
|
-0.040x |
|
Naos Ex-50 Opportunities Company Ltd
AU:NAC
|
0.047x |
|
Overactive Media Corp
V:OAM
|
-0.039x |
|
Century Extrusions Limited
NSE:CENTEXT
|
0.095x |
|
Greggs PLC
LSE:GRG
|
0.221x |
Annual Cash Flow Conversion Efficiency for NanoRepro AG (2013–2024)
The table below shows the annual cash flow conversion efficiency of NanoRepro AG from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see NanoRepro AG market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €38.14 Million ≈ $44.59 Million |
€9.86 Million ≈ $11.53 Million |
0.259x | +201.70% |
| 2023-12-31 | €40.38 Million ≈ $47.20 Million |
€-10.26 Million ≈ $-12.00 Million |
-0.254x | -191.73% |
| 2022-12-31 | €47.43 Million ≈ $55.45 Million |
€13.14 Million ≈ $15.37 Million |
0.277x | +95.60% |
| 2021-12-31 | €57.61 Million ≈ $67.35 Million |
€8.16 Million ≈ $9.54 Million |
0.142x | +200.82% |
| 2020-12-31 | €7.99 Million ≈ $9.34 Million |
€-1.12 Million ≈ $-1.31 Million |
-0.141x | -1.63% |
| 2019-12-31 | €4.43 Million ≈ $5.18 Million |
€-612.40K ≈ $-715.96K |
-0.138x | -201.53% |
| 2018-12-31 | €5.62 Million ≈ $6.57 Million |
€-257.60K ≈ $-301.16K |
-0.046x | +84.68% |
| 2017-12-31 | €3.82 Million ≈ $4.47 Million |
€-1.14 Million ≈ $-1.34 Million |
-0.299x | -18.04% |
| 2016-12-31 | €3.03 Million ≈ $3.55 Million |
€-769.70K ≈ $-899.86K |
-0.254x | +38.28% |
| 2015-12-31 | €2.27 Million ≈ $2.66 Million |
€-934.60K ≈ $-1.09 Million |
-0.411x | -43.01% |
| 2014-12-31 | €1.91 Million ≈ $2.23 Million |
€-548.00K ≈ $-640.67K |
-0.287x | +39.65% |
| 2013-12-31 | €1.64 Million ≈ $1.92 Million |
€-783.00K ≈ $-915.41K |
-0.476x | -- |
About NanoRepro AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more